# A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

> **NCT00923481** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Head and Neck Neoplasms
- Pheochromocytoma
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Fostamatinib disodium

## Key facts

- **NCT ID:** NCT00923481
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-04
- **Final completion:** 2012-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923481, "A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00923481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*